One of the leading biopharmaceutical companies, Cellectar Biosciences (NASDAQ: CLRB) focuses on treating patients with cancer by developing viable drugs. Unlike other biotech stocks CLRB recently, moves up slowly. Only COVID-19 vaccine developing firms see their stocks soar significantly and receive financial support from governments.
Last week CLRB bounced back to $1.44 but July’s $1.68 is yet to be recovered. Today CLRB rises 6.29% to $1.52 in the premarket. Without news, the stock manages to go up slowly.
A very weak part of the stock is the negative EPS which is normal for any healthcare company. Even long term investors may buy some shares to secure other losses in the future, perhaps, CLRB could grow further.
Finance and Tech Contributor